FFAR3 and fatty liver disease: The underlying molecular mechanism of sodium butyrate in preventing hepatic steatosis may be attributed to the activation of CaMKII‐CREB and inhibition of the HDAC1‐CREB signaling pathway via hepatic GPR41/43.